
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

**Date of Report: March 13, 2018
Commission File Number: 001-36891**

Collectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

<u>Exhibit</u>	<u>Title</u>
99.1	Press release, dated March 13, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLECTIS S.A.
(Registrant)

March 13, 2018

By: /s/ André Choulika
André Choulika
Chief Executive Officer

Dr. Mathieu Simon to Retire as Collectis' Chief Operating Officer; Elsy Boglioli Named as Successor

NEW YORK--(BUSINESS WIRE)--March 13, 2018--Regulatory News:

Collectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that Dr. Mathieu Simon is retiring as Executive Vice President and Chief Operating Officer, effective immediately. Following a smooth and successful transition over the last few months, Elsy Boglioli, Executive Vice President, Strategy and Corporate Development, is named Chief Operating Officer.

“Dr. Simon has been incredibly instrumental in the strategic and operational direction of the therapeutic activities at Collectis. Among his many achievements during his tenure, Dr. Simon helped to fundamentally transform Collectis from a research-oriented biotech company to a clinical-stage biopharma player. I warmly thank him for his service,” said Dr. André Choulika, Collectis Chief Executive Officer. “I look forward to Elsy Boglioli’s leadership as our new Chief Operating Officer as we enter the next phase of the Company’s development.”

Dr. Mathieu Simon has served as Collectis’ Executive Vice President since 2012 and as Chief Operating Officer since 2013. He was a member of Collectis’ board of directors as well.

“I am truly proud of our achievements at Collectis over the last six years, including building a solid product candidate portfolio, advancing two allogeneic product candidates developed by Collectis into the clinic and working strategically alongside our collaboration partners. It has been a great privilege to serve Collectis and I am now ready to retire with enthusiasm for the Company’s future, confidence in the work that the Collectis management team will continue, and gratitude for the many colleagues I have had the great pleasure to work with,” said Dr. Mathieu Simon. “I am delighted with Elsy Boglioli’s appointment as COO. Elsy brings a wealth of biopharmaceutical industry experience, having worked with leading pharmaceutical companies. Her unique blend of capabilities, relationships, and expertise will be invaluable assets to Collectis.”

About Collectis

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets.

Collectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by Collectis.

Disclaimer

This press release contains “forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Collectis makes with the Securities and Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

CONTACT:

Collectis

Media:

Jennifer Moore, 917-580-1088

VP of Communications

media@collectis.com

or

Caitlin Kasunich, 212-896-1241

KCSA Strategic Communications

ckasunich@kcsa.com

or

IR:

Simon Harnest, 646-385-9008

VP of Corporate Strategy and Finance

simon.harnest@collectis.com